Korro Bio Inc (KRRO) Stock Analysis
Verdict: AVOID
RNA editing pipeline offers high-upside clinical optionability, but severe cash burn ($79M FCF) and imminent dilution risk limit near-term upside.
Investment score: 38/100
Analysis as of
Is Korro Bio Inc stock worth reviewing? The TradeMates thesis
The TradeMates model evaluates Korro Bio (KRRO) as an AVOID at $13.20 USD due to an imminent funding shortfall. Annual FCF burn of -$79.1M against $21.8M in reported cash implies under 4 months of runway without capital raises, making secondary dilution highly probable.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Korro Bio Inc opportunities and risks
What speaks for KRRO
- Proprietary OPERATOR RNA Editing Platform
What speaks against KRRO
- Imminent Equity Dilution and Cash Runway Shortfall
Frequently asked questions about Korro Bio Inc (KRRO)
Is KRRO stock a good investment?
The TradeMates model rates Korro Bio Inc as AVOID with an investment score of 38/100. The TradeMates model evaluates Korro Bio (KRRO) as an AVOID at $13.20 USD due to an imminent funding shortfall. Annual FCF burn of -$79.1M against $21.8M in reported cash implies under 4 months of runway without capital raises, making secondary dilution highly probable. This is algorithmic model output, not personal investment advice.
Is KRRO stock a buy?
The TradeMates model verdict for KRRO is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.